TY - JOUR
T1 - Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia
AU - Spina, E.
AU - Avenoso, A.
AU - Facciolà, G.
AU - Salemi, M.
AU - Scordo, M. G.
AU - Ancione, M.
AU - Madia, A. G.
AU - Perucca, E.
PY - 2001
Y1 - 2001
N2 - Rationale: Evaluation of relationships between serum antipsychotic drug concentrations and clinical response may provide valuable information for rational dosage adjustments. For risperidone, this relationship has been little investigated to date. Objective: To assess the relationship between plasma concentrations of risperidone and its active 9-hydroxy-metabolite (9-OH-risperidone) and clinical response in schizophrenic patients who experienced an acute exacerbation of the disorder. Methods: Forty-two patients (30 males, 12 females, age 24-60 years) were given risperidone at dosages ranging from 4 to 9 mg/day for 6 weeks. The design of the study was open and risperidone dosage could be adjusted individually according to clinical response. Steady-state plasma concentrations of risperidone and its 9-hydroxymetabolite were measured after 4 and 6 weeks using a specific HPLC assay. Psychopathological state was assessed at baseline and at weeks 2, 4, and 6 by means of the positive and negative syndrome scale (PANSS), and patients were considered responders if they showed a greater than 20% reduction in total PANSS score at final evaluation compared with baseline. Results: Mean plasma concentrations of risperidone, 9-OH-risperidone, and active moiety (sum of risperidone and 9-OH-risperidone concentrations) did not differ between responders (n=28) and non-responders (n=14). No correlation between plasma levels and percent decrease in total PANSS score was found for risperidone (rs=-0.187, NS), 9-OH-risperidone (rs=0.246, NS), and active moiety (rs=0.249, NS). Active moiety concentrations in plasma were higher (P
AB - Rationale: Evaluation of relationships between serum antipsychotic drug concentrations and clinical response may provide valuable information for rational dosage adjustments. For risperidone, this relationship has been little investigated to date. Objective: To assess the relationship between plasma concentrations of risperidone and its active 9-hydroxy-metabolite (9-OH-risperidone) and clinical response in schizophrenic patients who experienced an acute exacerbation of the disorder. Methods: Forty-two patients (30 males, 12 females, age 24-60 years) were given risperidone at dosages ranging from 4 to 9 mg/day for 6 weeks. The design of the study was open and risperidone dosage could be adjusted individually according to clinical response. Steady-state plasma concentrations of risperidone and its 9-hydroxymetabolite were measured after 4 and 6 weeks using a specific HPLC assay. Psychopathological state was assessed at baseline and at weeks 2, 4, and 6 by means of the positive and negative syndrome scale (PANSS), and patients were considered responders if they showed a greater than 20% reduction in total PANSS score at final evaluation compared with baseline. Results: Mean plasma concentrations of risperidone, 9-OH-risperidone, and active moiety (sum of risperidone and 9-OH-risperidone concentrations) did not differ between responders (n=28) and non-responders (n=14). No correlation between plasma levels and percent decrease in total PANSS score was found for risperidone (rs=-0.187, NS), 9-OH-risperidone (rs=0.246, NS), and active moiety (rs=0.249, NS). Active moiety concentrations in plasma were higher (P
KW - 9-Hydroxy-risperidone
KW - Parkinsonism
KW - Plasma concentration
KW - Risperidone
KW - Schizophrenia
KW - Therapeutic drug monitoring
UR - http://www.scopus.com/inward/record.url?scp=0035140878&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035140878&partnerID=8YFLogxK
U2 - 10.1007/s002130000576
DO - 10.1007/s002130000576
M3 - Article
C2 - 11205425
AN - SCOPUS:0035140878
SN - 0033-3158
VL - 153
SP - 238
EP - 243
JO - Psychopharmacology
JF - Psychopharmacology
IS - 2
ER -